Epidemiology of Sleep-Disordered Breathing in Adults

描述(申请人提供)：睡眠障碍呼吸(SDB)，由睡眠中呼吸暂停和低呼吸事件的频率描述，被广泛认为是一种高度普遍但被低估的疾病，在高血压、心脑血管疾病、认知功能受损、睡眠过度、白天功能下降以及各种原因和心血管疾病的过早死亡中具有重要作用。20年来的人口研究已经证实了SDB的高患病率，并开始确定SDB的相关性和结果，但必须解决关键问题，以制定关于SDB预防和治疗的临床和公共卫生政策。将改变SDB负担的重要时期效应正在美国发生，包括二战后大量出生队列的老龄化，在中年期间对SDB风险因素有不同暴露的老年人的存活率提高，以及肥胖症的流行。在这些新的条件下，缺乏解决发展局公共卫生负担的数据。这里提出的研究旨在解决在理解未经治疗的SDB负担方面的差距。随着威斯康星睡眠队列研究的持续5年，这是一项关于SDB和其他睡眠障碍的纵向研究，我们将继续跟踪社区样本(n=1522)，这些样本包括基线年龄为30-60岁的男性和女性，他们在继续研究期间的年龄将达到55-85岁。通过长达25年的数据，结合SDB的个人数据轨迹和中老年的其他因素，我们将最佳地估计未经治疗的SDB在临床前和临床明显的心脑血管疾病(CVD/中风)、认知障碍和慢性日间功能障碍中的作用。我们还将调查与年龄相关的危险因素对睡眠障碍的影响。为了实现这些目标，我们将通过夜间多导睡眠监测、包括DXA、超声心动图和血管成像在内的最先进的身体习惯测量、神经心理学测试组件和其他测试来扩展我们关于SDB状态、风险因素和结果的丰富数据。

DESCRIPTION (provided by applicant): Sleep disordered breathing (SDB), described by the frequency of apnea and hypopnea events during sleep, is widely recognized as a highly prevalent but under-diagnosed condition that has a significant role in hypertension, cardiovascular and cerebrovascular disease, impaired cognitive function, hypersomnolence, decrements in daytime functioning and premature all-cause and cardiovascular mortality. Population studies over the 20 years have established the high prevalence of SDB and begun to identify the correlates and outcomes of SDB, but critical questions must be addressed to craft clinical and public health policy regarding the prevention and treatment of SDB. Important period effects that will change the SDB burden are occurring in the US, including aging of the large post World War II birth cohort, enhanced survival of older adults who have had different exposures during midlife to SDB risk factors, and an obesity epidemic. Data to address the public health burden of SDB under these new conditions are lacking. The research proposed here is designed to address the gap in understanding the burden of untreated SDB. With a 5-year continuation of the Wisconsin Sleep Cohort Study, a longitudinal study of SDB and other sleep disorders, we will continue to follow a community sample (n= 1522) of men and women, 30-60 years of age at baseline, who will have aged to 55-85 years over the continuation. With data spanning up to 25 years, with individual trajectories of data on SDB and other factors from middle to older age, we will optimally estimate the role of untreated SDB in preclinical and clinically evident cardiovascular and cerebrovascular disease (CVD/stroke), cognitive impairment, and chronic daytime dysfunction. We will also investigate the impact of age-related risk factors on sleep disorders. To achieve these goals, we will conduct follow-up protocols with overnight polysomnography, state of the art body habitus measures including DXA, echocardiography and vascular imaging, neuropsychologic test batteries, and other tests to extend our rich data on SDB status, risk factors, and outcomes.